Department of Medicine, Ludwig-Maximilians University (LMU) and Rudolf Marx Stiftung, Munich, Germany
Mini Review
COVID-19 Convalescent Plasma: No Definite Answer Yet
Author(s): Rainer Seitz*, Lutz Gürtler and Wolfgang Schramm
The COVID-19 pandemic so far caused millions of deaths, and the therapeutic options for high-risk patients are far from being satisfactory.
Active immunization by vaccines against SARS-CoV-2 spike protein provides good protection from a severe course of COVID-19. It has been
explored in numerous clinical trials, whether also passive immunization by transfusion of convalescent plasma could positively influence the
course of COVID-19. Large randomized clinical trials failed to demonstrate a benefit for patients with advanced disease. However, the
antibody dose and timing of transfusion might have contributed to this negative result. Randomized clinical trials are necessary to make
evidence-based progress in the development of therapeutic options, and this holds true also for “natural” concepts. However, even highquality
trials are just a tool to test predef.. Read More»
DOI:
10.37421/2165-7831.2021.11.265
Journal of Blood & Lymph received 443 citations as per Google Scholar report